GSK is in dispute with the US tax office over liabilities worth $680m
concerning the period 2001/03.
But if the IRS wins the claim in court,
GSK would expect to have an
‘additional liability for the four-year unaudited period 2004-07 proportionate
to its liability for the three-year audited period 2001-03’.
The extra liability is expected to push the bill over $1bn, but the extra
sums are unaudited and the company has therefore not briefed the market on the
GSK disputes the IRS charge and has said it ‘will vigorously contest’ it. If
the case goes to court, a resolution is not expected before 2010.
In its preliminary results announcement for the year ended 31 December 2007
GSK said it believes, ‘supported by external professional advice, that this
claim has no merit and that no adjustment is warranted’.
GSK is still discussing a transfer pricing issue with
HM Revenue & Customs.
The issues date back to 1994 and is likely to go to court given ‘a wide
difference between the group and HMRC positions’.
Read more at taxnews.pwc.com
The Financial Reporting Council has issued guidance regarding the annual reporting of 1,200 large and smaller listed companies. The letter highlighted the key issues and improvements that can be made in the 2016 reporting season
Baldwins Accountancy Group has continued investment in the north-east and appointed David Fish as a director in its corporate finance team
UK M&A activity bounced back strongly in July and August, according to analysis by the deals practice at PwC.
Smith & Williamson has added Jim Clark and Philip Marsden, of Marsden Clark Corporate Finance Limited, to its corporate finance team.